Grufity logoGrufity logo

Catalent Inc Stock Research

CTLT

65.94USD+1.27(+1.96%)Delayedas of 31 Mar 2023, 12:16 pm

Market Summary

USD65.94+1.27
Delayedas of 31 Mar 2023, 12:16 pm
1.96%

CTLT Stock Price

CTLT RSI Chart

CTLT Valuation

Market Cap

11.6B

Price/Earnings (Trailing)

28.39

Price/Sales (Trailing)

2.45

EV/EBITDA

20.26

Price/Free Cashflow

-31.38

CTLT Price/Sales (Trailing)

CTLT Profitability

EBT Margin

10.59%

Return on Equity

8.35%

Return on Assets

3.68%

Free Cashflow Yield

-3.19%

CTLT Fundamentals

CTLT Revenue

Revenue (TTM)

4.8B

Revenue Y/Y

-5.59%

Revenue Q/Q

12.43%

CTLT Earnings

Earnings (TTM)

410.0M

Earnings Y/Y

-16.49%

Earnings Q/Q

-100%

Price Action

52 Week Range

40.69115.34
(Low)(High)

Last 7 days

0.0%

Last 30 days

-5.2%

Last 90 days

43.7%

Trailing 12 Months

-41.6%

CTLT Financial Health

Current Ratio

1.91

Debt/Equity

0.86

Debt/Cashflow

0.08

CTLT Investor Care

Shares Dilution (1Y)

5.24%

Diluted EPS (TTM)

2.27

Peers (Alternatives to Catalent)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
403.2B
94.9B
0.11% -12.25%
22.47
4.25
1.25% -14.07%
306.9B
28.5B
9.47% 18.63%
49.14
10.75
0.79% 11.88%
272.8B
59.3B
0.39% 32.42%
17.88
4.63
21.72% 11.27%
226.4B
100.3B
-0.47% -21.10%
7.22
2.26
23.43% 42.74%
145.0B
46.2B
-1.10% -5.44%
22.92
3.14
-0.49% -9.54%
MID-CAP
4.8B
4.5B
-6.08% -6.58%
-33.89
1.07
7.56% -104.06%
3.3B
2.2M
188.80% 191.52%
-10.55
1.5K
-80.71% -4.88%
SMALL-CAP
1.9B
667.2M
-3.51% 11.94%
31.82
2.89
15.09% 13.64%
1.6B
602.5M
-7.75% -62.41%
-2.73
2.62
18.18% -18.59%
855.6M
478.9M
-23.48% -77.89%
-0.27
1.79
-31.50% -634.70%
771.4M
285.2M
-7.62% -41.93%
3.5
2.7
-27.21% -40.28%
719.3M
114.5M
-12.90% -53.56%
-4.26
6.28
27.90% 57.40%
555.5M
29.8M
-33.15% -52.78%
-6.39
18.67
340.05% 4.35%
398.4M
51.5M
-14.57% 2.18%
-5.61
7.74
18.32% -984.05%
94.1M
2.3B
-43.99% -88.43%
-0.03
0.04
-22.53% -376.66%

Financials for Catalent

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue-1.4%4,7574,8254,8284,7034,483
Gross Profit-1.1%1,5561,5741,6401,5911,534
  S&GA Expenses-0.2%855857844802768
  R&D Expenses-4.3%22.0023.0024.0021.00-
EBITDA-1.4%761772860843-
EBITDA Margin0.0%0.16*0.16*0.18*0.18*-
Earnings Before Taxes-0.2%504505605615756
EBT Margin1.2%0.11*0.10*0.13*0.13*-
Interest Expenses-11.6%-144-129-123-123-117
Net Income-3.8%410426519513604
Net Income Margin-2.4%0.09*0.09*0.11*0.11*-
Free Cahsflow21.2%-371-471-221-110-
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets9.2%11,14710,20510,50710,32210,203
  Current Assets8.2%2,9182,6982,9163,0252,974
    Cash Equivalents57.3%442281449786849
  Inventory11.7%818732702676688
  Net PPE13.0%3,5793,1673,1272,8202,727
  Goodwill9.8%3,2152,9293,0063,0123,026
Liabilities13.3%6,2355,5055,7125,6905,722
  Current Liabilities61.8%1,5269431,0721,0461,045
  Long Term Debt3.0%4,2214,0984,1714,1574,191
Shareholder's Equity4.5%4,9124,7004,7954,6324,481
  Retained Earnings15.1%619538538350209
  Additional Paid-In Capital0.3%4,6864,6744,6494,6304,615
Accumulated Depreciation7.9%1,4651,3581,3471,3081,215
Shares Outstanding0%180180179179171
Float-21,840----
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations78.8%329184439504441
  Share Based Compensation-1.9%51.0052.0054.0055.0060.00
Cashflow From Investing28.6%-1,309-1,833-1,884-1,703-1,594
Cashflow From Financing2487.0%59523.001,0311,0131,182

Risks for CTLT

What is the probability of a big loss on CTLT?

65.4%


Probability that Catalent stock will be more than 20% underwater in next one year

55.8%


Probability that Catalent stock will be more than 30% underwater in next one year.

10.8%


Probability that Catalent stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does CTLT drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Catalent was unfortunately bought at previous high price.

Drawdowns

Returns for CTLT

Cumulative Returns on CTLT

13.5%


7-Year Cumulative Returns

9.5%


5-Year Cumulative Returns

8.6%


3-Year Cumulative Returns

What are the long-term rolling returns for CTLT?

FIve years rolling returns for Catalent.

Annualized Returns

Which funds bought or sold CTLT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-27
Neo Ivy Capital Management
added
16,557
282,000
285,000
0.19%
2023-03-23
MetLife Investment Management, LLC
reduced
-0.81
-1,375,980
2,216,470
0.02%
2023-03-17
American Portfolios Advisors
added
5.72
-30,144
74,893
-%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
added
17.75
-1,463,000
4,004,000
-%
2023-03-06
NORTH STAR ASSET MANAGEMENT INC
added
17.63
-1,140,120
3,109,880
0.19%
2023-03-06
Rockefeller Capital Management L.P.
reduced
-74.97
-6,635,000
1,222,000
0.01%
2023-02-28
Voya Investment Management LLC
added
30.19
-3,101,880
13,205,100
0.02%
2023-02-24
NATIXIS
sold off
-100
-2,339,000
-
-%
2023-02-24
National Pension Service
reduced
-99.98
-18,756,100
2,025
-%
2023-02-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
-456,000
752,000
0.01%

1–10 of 48

Latest Funds Activity

Are funds buying CTLT calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own CTLT
No. of Funds

Catalent News

GuruFocus.com

Bronstein, Gewirtz & Grossman, LLC Notifies Catalent, Inc. (CTLT ....

GuruFocus.com,
2 hours ago

Investor's Business Daily

Zacks Investment Research

InvestorsObserver

Catalent Shareholder Action Reminder.

InvestorsObserver,
42 hours ago

Yahoo Finance

Schedule 13G FIlings of Catalent

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
t. rowe price investment management, inc.
9.2%
16,578,946
SC 13G/A
Feb 13, 2023
capital world investors
7.7%
13,914,820
SC 13G/A
Feb 09, 2023
janus henderson group plc
4.6%
8,216,242
SC 13G/A
Feb 09, 2023
vanguard group inc
10.88%
19,588,103
SC 13G/A
Feb 07, 2023
blackrock inc.
7.7%
13,788,094
SC 13G/A
Jan 27, 2023
veritas asset management llp
6.21%
11,169,815
SC 13G
Feb 14, 2022
price t rowe associates inc /md/
10.8%
18,616,482
SC 13G/A
Feb 11, 2022
capital world investors
6.2%
10,577,293
SC 13G
Feb 09, 2022
vanguard group inc
10.79%
18,479,271
SC 13G/A
Feb 03, 2022
blackrock inc.
8.8%
14,998,086
SC 13G/A

CTLT Fair Value

Catalent fair value in different scenarios

The table shows the Fair Value estimates for Catalent for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

52.48

-20.41%

66.72

1.19%

94.66

43.57%

131.81

99.91%

165.84

151.52%
Current Inflation

48.38

-26.62%

60.51

-8.23%

83.99

27.38%

115.25

74.79%

143.74

118.00%
Very High Inflation

43.32

-34.30%

53.04

-19.56%

71.45

8.36%

96.07

45.70%

118.36

79.51%

Historical Catalent Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Catalent

View All Filings
Date Filed Form Type Document
Feb 21, 2023
3
Insider Trading
Feb 14, 2023
SC 13G/A
Major Ownership Report
Feb 13, 2023
SC 13G/A
Major Ownership Report
Feb 09, 2023
SC 13G/A
Major Ownership Report
Feb 09, 2023
SC 13G/A
Major Ownership Report
Feb 07, 2023
SC 13G/A
Major Ownership Report
Feb 07, 2023
8-K
Current Report
Feb 07, 2023
10-Q
Quarterly Report
Feb 06, 2023
3
Insider Trading
Jan 27, 2023
SC 13G
Major Ownership Report

Latest Insider Trading transactions for CTLT

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-01-23
Hopson Ricky
sold
-31,738
49.36
-643
pres. clinical dev supply div
2022-12-05
Boerman Manja
sold
-40,326
51.7
-780
pres. biomodalities division
2022-10-31
Grippo Michael J
sold
-161,349
65.83
-2,451
svp, strategy & corp. dev.
2022-10-27
Barber Michael J
acquired
-
-
4,149
-
2022-10-27
GREISCH JOHN J
acquired
-
-
4,149
-
2022-10-27
Balachandran Madhavan
acquired
-
-
4,149
-
2022-10-27
MOREL DONALD E JR
acquired
-
-
4,149
-
2022-10-27
CLASSON ROLF A
acquired
-
-
4,149
-
2022-10-27
Kreuzburg Christa
acquired
-
-
4,149
-
2022-10-27
STAHL JACK L
acquired
-
-
4,149
-

1–10 of 50

John R. Chiminski
17300
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.

CTLT Income Statement

2022-09-30
Consolidated Statements of Operations - USD ($)
$ in Millions
3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]  
Net revenue$ 1,022.0$ 1,025.0
Cost of sales764.0701.0
Gross margin258.0324.0
Selling, general, and administrative expenses196.0183.0
Payments for (Proceeds from) Businesses and Interest in Affiliates[1]0.0(1.0)
Other Cost and Expense, Operating2.04.0
Operating earnings60.0138.0
Interest expense, net32.026.0
Other (income)/expense, net[2]25.09.0
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Total3.0103.0
Income tax expense3.010.0
Net earnings/(loss)0.093.0
Participating Securities, Distributed and Undistributed Earnings (Loss), Basic0.09.0
Net Income (Loss) Available to Common Stockholders, Basic$ 0.0$ 84.0
Earnings Per Share, Basic$ 0$ 0.49
Earnings Per Share, Diluted$ 0$ 0.49
[1]Gain on sale of subsidiary for the three months ended September 30, 2021 was due to the sale of the facility in Woodstock, Illinois and the associated business
[2]Other expense, net during the three months ended September 30, 2022 includes foreign currency remeasurement losses/gains.Other expense, net during the three months ended September 30, 2021 includes financing charges related to the Company’s Incremental Term B-3 Loans and foreign currency remeasurement losses/gains.

CTLT Balance Sheet

2022-09-30
Consolidated Balance Sheets - USD ($)
$ in Millions
Sep. 30, 2022
Jun. 30, 2022
Current assets:  
Cash and cash equivalents$ 281$ 449
Trade receivables, net9891,051
Inventories732702
Prepaid expenses and other632625
Marketable Securities6489
Total current assets2,6982,916
Property, plant, and equipment, net3,1673,127
Other assets:  
Goodwill2,9293,006
Other intangibles, net1,0171,060
Deferred Income Tax Assets, Net4549
Other Assets, Noncurrent349349
Total assets10,20510,507
Current Liabilities:  
Debt, Current10631
Accounts payable379421
Other accrued liabilities458620
Total current liabilities9431,072
Long-term obligations, less current portion4,0984,171
Pension liability98103
Deferred Income Taxes214202
Other liabilities152164
Total liabilities5,5055,712
Temporary Equity, Carrying Amount, Attributable to Parent$ 0$ 0
Common Stock, Par or Stated Value Per Share$ 0.01$ 0.01
Common Stock, Shares Authorized1,000,000,0001,000,000,000
Common Stock, Value, Outstanding$ 2$ 2
Preferred Stock, Value, Outstanding00
Additional paid in capital4,6744,649
Accumulated deficit538538
Accumulated other comprehensive income/(loss)(514)(394)
Total shareholders' equity4,7004,795
Total liabilities, redeemable preferred stock, and shareholders’ equity$ 10,205$ 10,507
Common stock, shares issued (shares)180,000,000179,000,000